A Phase II trial of ZLX-1 for treating stress-related insomnia.

Trial Profile

A Phase II trial of ZLX-1 for treating stress-related insomnia.

Planning
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2017

At a glance

  • Drugs ZLX 1 (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Aug 2017 According to a Blake Insomnia Therapeutics media release, the company has submitted its clinical trial application (CTA) for Phase II clinical testing to Health Canada.
    • 25 Feb 2017 According to a Blake Insomnia Therapeutics media release, company is planning to submit a New Drug Application in Canada with US in Q2 2017 and International submissions to follow later.
    • 08 Feb 2017 According to Blake Insomnia Therapeutics media release, this trial is planned for Q2 2017, with successful filing and approval, the product is expected to be launched in the US in 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top